News
MCRB
0.8327
-0.86%
-0.0072
Weekly Report: what happened at MCRB last week (0203-0207)?
Weekly Report · 5d ago
Seres Therapeutics Expands Board with Nestlé’s Appointee
TipRanks · 02/06 13:35
Weekly Report: what happened at MCRB last week (0127-0131)?
Weekly Report · 02/03 09:06
Weekly Report: what happened at MCRB last week (0120-0124)?
Weekly Report · 01/27 09:06
Investors in Seres Therapeutics (NASDAQ:MCRB) from three years ago are still down 88%, even after 17% gain this past week
Simply Wall St · 01/23 10:46
Weekly Report: what happened at MCRB last week (0113-0117)?
Weekly Report · 01/20 09:05
Seres Therapeutics announces receipt of expected $50M installment payment
TipRanks · 01/16 12:05
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 01/16 12:05
SERES THERAPEUTICS ANNOUNCES RECEIPT OF EXPECTED $50 MILLION INSTALLMENT PAYMENT RELATED TO VOWST SALE
Reuters · 01/16 12:00
Press Release: Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
Dow Jones · 01/16 12:00
Seres Therapeutics Strengthens Future with VOWST Sale
TipRanks · 01/13 13:44
Weekly Report: what happened at MCRB last week (0106-0110)?
Weekly Report · 01/13 09:06
Seres Therapeutics (MCRB) Receives a Buy from TD Cowen
TipRanks · 01/10 12:18
Seres Therapeutics Reports Positive Biomarker Data From SER-155 Phase 1b Study
NASDAQ · 01/09 15:58
Seres announces new translational biomarker results from SER-155 Phase 1b study
TipRanks · 01/09 12:15
Seres Therapeutics Announced New Translational Biomarker Results For Exploratory Endpoints From Its SER-155 Phase 1b Placebo-controlled Study In Patients Undergoing Allogenic Stem Cell Transplantation
Benzinga · 01/09 12:13
SERES THERAPEUTICS INC - SER-155 SHOWS 77% RELATIVE RISK REDUCTION IN BLOODSTREAM INFECTIONS
Reuters · 01/09 12:00
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
Barchart · 01/09 06:00
Weekly Report: what happened at MCRB last week (1230-0103)?
Weekly Report · 01/06 09:06
Weekly Report: what happened at MCRB last week (1223-1227)?
Weekly Report · 12/30/2024 09:06
More
Webull provides a variety of real-time MCRB stock news. You can receive the latest news about Seres Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About MCRB
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The Company is engaged in developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The Company's clinical and nonclinical data across its programs support the development of live biotherapeutics to target the prevention and treatment of a broad swath of infections, and in inflammatory and immune diseases.